Administration of study and clinical trials
Read this section in the full bill →
This section appears in one version only, so there is nothing to compare yet.
(a) Demographic representation In carrying out the study required by section 2 and the clinical trials required by section 3, the Secretary shall ensure representation in such study and trials of demographics that represent the population of veterans in the United States, as determined by the most recently available data from the American Community Survey of the Bureau of the Census. (b) Data preservation The Secretary shall ensure that the study required by section 2 and the clinical trials required by section 3 include a mechanism to ensure— (1) the preservation of all data, including all data sets and survey results, collected or used for purposes of such study and trials in a manner that will facilitate further research; and (2) registration of such data in the database of privately and publicly funded clinical studies maintained by the National Library of Medicine (or successor database). (c) Anonymous data The Secretary shall ensure that data relating to any study or clinical trial conducted under this Act is anonymized and cannot be traced back to an individual patient. (d) Effect on other benefits The eligibility or entitlement of a covered veteran to any other benefit under the laws administered by the Secretary or any other provision of law shall not be affected by the participation of the covered veteran in the study under section 2, a clinical trial under section 3(a), or a study under section 3(b). (e) Effect on other laws Nothing in this Act shall affect or modify— (1) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.); (2) section 351 of the Public Health Service Act (42 U.S.C. 262); or (3) the authority of the Commissioner of Food and Drugs and the Secretary of Health and Human Services— (A) under— (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.); or (ii) section 351 of the Public Health Service Act (42 U.S.C. 262); or (B) to promulgate Federal regulations and guidelines pertaining to cannabidiol, marijuana, or other subject matter addressed in this Act.